For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Tafamidis and the formulated version represents a genuine breakthrough . These innovative therapies preserve the transthyretin protein, halting its harmful build-up and reducing the severity of the illness. Patients are now seeing p